Recently, Swiss pharmaceutical giant Novartis made history as the first company to win FDA approval for a CAR-T therapy in the Unites States. Novartis announced that its genetically modified autologous (“self-derived”) immunocellular therapy, Kymriah, will cost $475,000 per treatment course. This week, Kite Pharma announced the approval of its CAR-T therapy, Yescarta, in the U.S. with a list price of $373,000.
While these prices are expensive, they are far from trendsetting. [Read more…]